FDA might call a drug a ‘breakthrough,’ but investors don’t seem to care, study finds
Researchers examined FDA Breakthrough Therapy Designations over a six-year period, but found they had little effect on companies' stock prices.
Researchers examined FDA Breakthrough Therapy Designations over a six-year period, but found they had little effect on companies' stock prices.